Trial Profile

First-in-human Phase 1 trial of VENT-03 in healthy volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VENT 03 (Primary)
Indications Immunological disorders; Inflammation; Skin disorders; Systemic lupus erythematosus
Focus Adverse reactions; First in man

Most Recent Events

22 May 2025 According to a Ventus Therapeutics Media Release, data from the study were presented at the 16th International Congress on Systemic Lupus Erythematosus (LUPUS 2025),
22 May 2025 Results presented in the Ventus Therapeutics Media Release
31 Oct 2024 According to a Ventus Therapeutics Media Release, company plans to present full data from the Phase 1 trial at a future medical conference.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com